Table 2.
Relationships between the expression of Aurora B and clinical pathological characteristics in 80 patients with ESCC.
| Expression of Aurora B |
p – value | |||
|---|---|---|---|---|
| Characteristics | All cases | Low(n = 35) | High(n = 45) | |
| Gender | 0.999 | |||
| Male | 64 | 28 | 36 | |
| Female | 16 | 7 | 9 | |
| Age(years) | 0.806 | |||
| ≤ 60 | 24 | 11 | 13 | |
| > 60 | 56 | 24 | 32 | |
| Initial clinical stage | ||||
| ≤ IIa | 40 | 19 | 21 | 0.499 |
| > IIa | 40 | 16 | 24 | |
| Tumor stages | 0.088 | |||
| T1 + T2 | 22 | 13 | 9 | |
| T3 + T4 | 58 | 22 | 36 | |
| Lymph nodes status | 0.013⁎ | |||
| N0 (negative) | 40 | 23 | 17 | |
| N1 or above (positive) | 40 | 12 | 28 | |
Chi-square test.
⁎
p < 0.05 indicates a significant upregulation of Aurora B in patients with lymphatic metastasis vs. no lymphatic metastasis.